Editorial Comment to “Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma”
Authors:
- 18 July 2025
- journal article
- Published by Wiley in International Journal of Urology
- Vol. 32 (10) , 1462-1463
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Real-world effectiveness and treatment (tx) patterns in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in Japan: Results from the JAVEMACS chart review study.Journal of Clinical Oncology, 2025
- Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trialCancer Medicine, 2024
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-UpJournal of Clinical Oncology, 2023
- Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trialNature Medicine, 2021